← All trials
NCT07285278
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2025
- Primary completion
- Apr 15, 2026
- Completion date
- Feb 15, 2027
- First posted
- Dec 16, 2025
- Last posted
- Dec 16, 2025
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Abogen Biosciences Co. Ltd.Lead sponsor
- Abogen Biosciences Co. Ltd.Collaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.